BackgroundComplement activation in atypical hemolytic uremic syndrome (aHUS), C3 glomerulonephropathy (C3G) and immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) may be associated with rare genetic variants. Here we describe gene variants in the Swedish and Norwegian populations.MethodsPatients with these diagnoses (N=141) were referred for genetic screening. Sanger or next-generation sequencing were performed to identify genetic variants in 16 genes associated with these conditions. Nonsynonymous genetic variants are described when they have a minor allele frequency of ResultsIn patients with aHUS (n=94, one also had IC-MPGN) 68 different genetic variants or deletions were identified in 60 patients, of which 18 wer...
Introduction: The glomerulonephritides are a group of heterogeneous disorders which can occur as pri...
Background and objectives: Atypical hemolytic uremic syndrome (aHUS) is associated with mutations in...
Contains fulltext : 88523.pdf (publisher's version ) (Closed access)BACKGROUND: At...
BackgroundComplement activation in atypical hemolytic uremic syndrome (aHUS), C3 glomerulonephropath...
BackgroundComplement activation in atypical hemolytic uremic syndrome (aHUS), C3 glomerulonephropath...
BackgroundComplement activation in atypical hemolytic uremic syndrome (aHUS), C3 glomerulonephropath...
INTRODUCTION: Complement-mediated atypical hemolytic uremic syndrome (aHUS) is an ultra-rare renal d...
Complement-mediated kidney diseases are ultrarare conditions characterized by excess complement acti...
Background Primary membranoproliferative GN, including complement 3 (C3) glomerulopathy, is a rare, ...
Glomerulonephritis (GN) is a complex disease with intricate underlying pathogenic mechanisms. The po...
Several abnormalities in complement genes reportedly contribute to atypical hemolytic uremic syndrom...
SummaryBackgroundComplement is a key component of the innate immune system, and variation in genes t...
This study examines the prevalence and distribution of genetic kidney diseases in a cohort of chroni...
INTRODUCTION: Abnormal control of the complement alternative pathway (CAP) (factor H, factor I and m...
Rationale: C3 glomerulonephritis (C3GN) and complement-mediated hemolytic uremic syndrome (HUS) both...
Introduction: The glomerulonephritides are a group of heterogeneous disorders which can occur as pri...
Background and objectives: Atypical hemolytic uremic syndrome (aHUS) is associated with mutations in...
Contains fulltext : 88523.pdf (publisher's version ) (Closed access)BACKGROUND: At...
BackgroundComplement activation in atypical hemolytic uremic syndrome (aHUS), C3 glomerulonephropath...
BackgroundComplement activation in atypical hemolytic uremic syndrome (aHUS), C3 glomerulonephropath...
BackgroundComplement activation in atypical hemolytic uremic syndrome (aHUS), C3 glomerulonephropath...
INTRODUCTION: Complement-mediated atypical hemolytic uremic syndrome (aHUS) is an ultra-rare renal d...
Complement-mediated kidney diseases are ultrarare conditions characterized by excess complement acti...
Background Primary membranoproliferative GN, including complement 3 (C3) glomerulopathy, is a rare, ...
Glomerulonephritis (GN) is a complex disease with intricate underlying pathogenic mechanisms. The po...
Several abnormalities in complement genes reportedly contribute to atypical hemolytic uremic syndrom...
SummaryBackgroundComplement is a key component of the innate immune system, and variation in genes t...
This study examines the prevalence and distribution of genetic kidney diseases in a cohort of chroni...
INTRODUCTION: Abnormal control of the complement alternative pathway (CAP) (factor H, factor I and m...
Rationale: C3 glomerulonephritis (C3GN) and complement-mediated hemolytic uremic syndrome (HUS) both...
Introduction: The glomerulonephritides are a group of heterogeneous disorders which can occur as pri...
Background and objectives: Atypical hemolytic uremic syndrome (aHUS) is associated with mutations in...
Contains fulltext : 88523.pdf (publisher's version ) (Closed access)BACKGROUND: At...